Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome
2期
已完成
NCT03905525
| 适应症 | Sjögren Syndrome |
|---|
| 分期 | 2期 |
|---|
| 申办方 | Novartis Pharmaceuticals |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 273 人 |
|---|
| 干预（药物） | CFZ533 |
|---|
| 开始日期 | 2019年10月1日 |
|---|
| 完成日期 | 2022年9月28日 |
|---|
| 结果公布日 | 2026年5月18日 |
|---|
摘要
This study was to evaluate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of CFZ533 (iscalimab) in patients with Sjögren's Syndrome (SjS).
Cohort 1: Change in EULAR Sjögren Syndrome Disease Activity Index (ESSDAI) Score From Baseline at 24 Weeks as Compared to Placebo
Baseline, Week 24 · Unit on a scale
| Cohort 1 / Arm D (Period 1): Placebo | -4.0 ± 0.73 Unit on a scale |
|---|
| Cohort 1/Arm C: CFZ533 150 mg | -7.0 ± 0.70 Unit on a scale |
|---|
| Cohort 1/Arm B: CFZ533 300 mg | -5.4 ± 0.71 Unit on a scale |
|---|
| Cohort 1/Arm A: CFZ533 600 mg | -6.9 ± 0.73 Unit on a scale |
|---|
| p-value | 0.0025 |
|---|
| LS Mean difference CFZ533-Placebo | -3.0 (95% CI -4.9–-1.1) |
|---|
Cohort 2: Change in EULAR Sjögren Syndrome Patient Reported Index (ESSPRI) Score From Baseline at 24 Weeks as Compared to Placebo.
Baseline, Week 24 · Unit on a scale
| Cohort 2/Arm F: Placebo | -1.21 ± 0.271 Unit on a scale |
|---|
| Cohort 2/Arm E: CFZ533 600 mg | -1.79 ± 0.258 Unit on a scale |
|---|
| p-value | 0.1210 |
|---|
| LS Mean difference CFZ533-Placebo | -0.57 (95% CI -1.30–0.15) |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
同一适应症的其他试验
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。